Development of targeted 1,2-diacyl-sn-glycero-3-phospho-l-serine-coated gelatin nanoparticles loaded with amphotericin B for improvedin vitroandin vivoeffect in leishmaniasis

Development of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: a system for intervention in visceral leishmaniasis

(2012) S. Kansal et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Exploiting 4-sulphateN-acetyl galactosamine decorated gelatin nanoparticles for effective targeting to professional phagocytesin vitroandin vivo

(2012) Pankaj Dwivedi et al.   JOURNAL OF DRUG TARGETING

Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis

(2010) Gaurav Kant Saraogi et al.   JOURNAL OF DRUG TARGETING

Development and characterization of oral lipid-based Amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans

(2009) Ellen K. Wasan et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Amphotericin B lipid preparations: what are the differences?

(2008) J.P. Adler-Moore et al.   CLINICAL MICROBIOLOGY AND INFECTION

The Relationship between Leishmaniasis and AIDS: the Second 10 Years

(2008) J. Alvar et al.   CLINICAL MICROBIOLOGY REVIEWS

Amphotericin B Formulations and Drug Targeting

(2007) J.J. Torrado et al.   JOURNAL OF PHARMACEUTICAL SCIENCES